Compare Stocks → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:LXGTSE:ONC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXGLexaGeneC$0.11-19.2%C$0.11C$0.07▼C$0.31C$14.77M2.26170,061 shs2.14 million shsONCOncolytics BiotechC$1.44+0.7%C$1.44C$1.20▼C$4.49C$108.61M1.4979,338 shs23,577 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXGLexaGene0.00%0.00%0.00%0.00%0.00%ONCOncolytics Biotech-0.69%-10.06%+2.88%-11.73%-7.74%Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLXGLexaGeneN/AN/AN/AN/AN/AN/AN/AN/AONCOncolytics Biotech0.6476 of 5 stars3.50.00.00.01.30.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXGLexaGeneN/AN/AN/AN/AONCOncolytics Biotech3.00BuyC$6.00316.67% UpsideCurrent Analyst RatingsLatest LXG, ONC, OSL, and YGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperformC$3.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXGLexaGeneC$110.93K133.13C$0.00 per share21.25C$0.01 per share10.50ONCOncolytics BiotechN/AN/AC$0.34 per share4.22C$0.37 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXGLexaGene-C$8.54M-C$0.08N/A∞N/AN/A-339.54%-120.21%N/AONCOncolytics Biotech-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)Latest LXG, ONC, OSL, and YGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCOncolytics Biotech-C$0.15-C$0.05+C$0.10-C$0.05N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLXGLexaGeneN/AN/AN/AN/AN/AONCOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXGLexaGene138.011.391.13ONCOncolytics Biotech1.549.018.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXGLexaGene0.09%ONCOncolytics Biotech6.98%Insider OwnershipCompanyInsider OwnershipLXGLexaGene17.85%ONCOncolytics Biotech6.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLXGLexaGene41140.64 millionN/ANot OptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableLXG, ONC, OSL, and YGEN HeadlinesSourceHeadlineOutrun Therapeutics announces launch with $10m seed fundingpharmaceutical-technology.com - April 18 at 7:38 AMBiotech expansion for Japanese firm in Holly Springs driven by talent pool, universitiescarolinapublicpress.org - April 17 at 10:38 AMStocks in play: Oncolytics Biotech® Inc.ca.finance.yahoo.com - April 11 at 3:56 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAfinance.yahoo.com - April 11 at 8:38 AMTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024markets.businessinsider.com - April 10 at 6:01 PMOncolytics Biotech is undervalued, Raymond James sayscantechletter.com - April 5 at 3:37 PMOncolytics Biotech (TSE:ONC) Trading Up 10.7%marketbeat.com - April 4 at 10:46 AMClosing Bell: Oncolytics Bio down on Friday (ONC)theglobeandmail.com - March 16 at 10:14 AMFutures Retreat Sharplymsn.com - March 11 at 4:05 PMOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANfinanznachrichten.de - March 6 at 4:39 PMEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winningfinanznachrichten.de - March 6 at 4:39 PMA Preview Of Oncolytics Biotech's Earningsbenzinga.com - March 6 at 4:39 PMOncolytics Biotech Inc ONCmorningstar.com - March 2 at 6:22 PMReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipelinemarkets.businessinsider.com - February 15 at 9:24 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsfinance.yahoo.com - February 15 at 9:24 AMAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapiestheglobeandmail.com - February 14 at 2:36 PMUSA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024finanznachrichten.de - February 7 at 11:03 AMKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Virusesfinance.yahoo.com - January 31 at 8:47 PMOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 6 at 3:30 PMJonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)markets.businessinsider.com - December 14 at 8:26 AMOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSfinanznachrichten.de - December 7 at 8:30 AMOncolytics Provides Update on Pancreatic Cancer Program for Pelareorepfinance.yahoo.com - November 9 at 7:48 AMOncolytics Biotech's Earnings Outlookbenzinga.com - November 3 at 6:37 PMOncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlightsfinanznachrichten.de - November 3 at 1:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesCanoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetTesla Stock Drops on Weak Delivery Numbers and it May Fall MoreApril 2, 2024 11:25 AMView Tesla Stock Drops on Weak Delivery Numbers and it May Fall MoreIntel's Foundry Woes: Sell Signal or Silver Lining Ahead?April 5, 2024 8:45 AMView Intel's Foundry Woes: Sell Signal or Silver Lining Ahead?Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?March 26, 2024 7:00 AMView Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?Cannabis: One Stock to Play the MovementApril 8, 2024 8:38 AMView Cannabis: One Stock to Play the MovementAll Headlines Company DescriptionsLexaGeneCVE:LXGLexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.Oncolytics BiotechTSE:ONCOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.